The Pfizer vaccine makes people less immune to the coronavirus

The Pfizer vaccine makes people less immune to what is alleged to be one of the most deadly Covid-19 variants, it has been revealed. 

A scientific study from the Francis Crick Institute found that people who had the Pfizer jab were actually more vulnerable to the Delta (Indian) variant.

According to the research, levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK.

This is the largest study published to date investigating the vaccine-induced antibody neutralising capacity against the newest variants of concern in healthy adults. 

Researchers have submitted their findings to the Genotype-to-Phenotype National Virology Consortium (G2P-UK), the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and the Joint Committee on Vaccination and Immunisation (JCVI), as evidence of the lower levels of antibodies than those who had the Covid-19 vaccine produces. 

Researchers gathered blood samples from healthcare workers and staff from the institutions have been donating regular blood and swab samples.

They found that in people who had been fully vaccinated with two doses of the Pfizer-BioNTech vaccine, levels of neutralising antibodies were more than five times lower* against the B.1.617.2 variant when compared to the original strain.

The study participants analysed here had all been vaccinated with the Pfizer-BioNTech vaccine.

According to the researchers at the Crick Institute, more work needs to be done to see how effective the other vaccines are in preventing the Covid-19 virus and its variants. In other words, this phase of the vaccine trial is still ongoing.

The study research stated: “More work is underway to test neutralising antibodies against these same variants in people who have been vaccinated with the Oxford/AstraZeneca vaccine.”

David LV Bauer, group leader of the Crick’s RNA Virus Replication Laboratory and member of the G2P-UK National Virology Consortium, said: 

“Keeping track of these evolutionary changes is essential for us to retain control over the pandemic and return to normality. This work is a powerful example of effective collaborations between NHS and academic colleagues, that can help us to navigate changes in this new phase of the pandemic.”

Leave a Reply

Your email address will not be published. Required fields are marked *


(Spamcheck Enabled)